Antagonismo del Sistema Endocanabinoide: Implicaciones en el tratamiento de la obesidad, síndrome metabólico y adición a drogas
Sonia Tucci(University of Liverpool), Tim C. Kirkham(University of Liverpool)
Revista Venezolana de Endocrinología y Metabolismo
June 1, 2006
Cited by 0
Related Papers
Cannabinoids and Ghrelin Have Both Central and Peripheral Metabolic and Cardiac Effects via AMP-activated Protein Kinase
|Journal of Biological Chemistry|2005|469
The cannabinoid CB<sub>1</sub> receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin
|British Journal of Pharmacology|2004|184
Nicotinic–serotonergic interactions in brain and behaviour
|Pharmacology Biochemistry and Behavior|2002|149
The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
|Diabetes Metabolic Syndrome and Obesity|2010|146
The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
|Diabetes Metabolic Syndrome and Obesity|2010|144